Angiotensin II as candidate of cardiac cachexia

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 9, Issue 3, 2006, Pages 220-224

  Delafontaine, Patrice ^a   Akao, Makoto ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Atrophy; Insulin like growth factor 1; Muscle wasting; Ubiquitin proteasome pathway

Indexed keywords

ANGIOTENSIN II; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN KINASE B; SOMATOMEDIN C; TRANSCRIPTION FACTOR FOXO; UBIQUITIN PROTEIN LIGASE;

ANOREXIA; CACHEXIA; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; DOWN REGULATION; DUCHENNE MUSCULAR DYSTROPHY; ENZYME ACTIVITY; GENE OVEREXPRESSION; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SKELETAL MUSCLE; UPREGULATION; WEIGHT REDUCTION;

ANGIOTENSIN II; CACHEXIA; HEART FAILURE, CONGESTIVE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MUSCLE, SKELETAL; MUSCULAR ATROPHY;

ANIMALIA;

EID: 33746228328     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/01.mco.0000222103.29009.70     Document Type: Review

References (61)

1. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349:1050-1053.
2. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005; 37:1974-1984.
3. Bhatia V, Bhatia R, Mathew B. Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies. Cardiol Rev 2005; 13:297-303.
4. Attaix D, Ventadour S, Codran A, et al. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem 2005; 41:173-186. Recent review of involvement of the ubiquitin-proteasome pathway in skeletal muscle wasting.
5. Herrmann J, Ciechanover A, Lerman LO, Lerman A. The ubiquitin-proteasome system in cardiovascular diseases - a hypothesis extended. Cardiovasc Res 2004; 61:11-21. Review of the involvement of the ubiquitin-proteasome pathway in cardiovascular diseases.
6. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426:895-899.
7. Schoenheimer R. Dynamic state of body constituents. Cambridge: Harvard University Press; 1942.
8. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294:1704-1708.
9. Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 2001; 98:14440-14445.
10. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117:399-412. The authors characterize the function of FOXO transcription factors in atrophying muscle and their role in transcriptional regulation of the ubiquitin ligase atrogin-1.
11. Iaina A, Silverberg DS, Wexler D. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome. Nat Clin Pract Cardiovasc Med 2005; 2:95-100.
12. Kuroda T, Shida H. Angiotensin II-induced myocardial damage with a special reference to low cardiac output syndrome. Jpn Heart J 1983; 24:235-243.
13. Strassburg S, Springer J, Anker SD. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol 2005; 37:1938-1947.
14. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996; 97:2509-2516.
15. Brink M, Price SR, Chrast J, et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 2001; 142:1489-1496.
16. May RC, Kelly RA, Mitch WE. Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. J Clin Invest 1986; 77:614-621.
17. Mitch WE, Bailey JL, Wang X, et al. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 1999; 276:C1132-C1138.
18. Du J, Mitch WE. Identification of pathways controlling muscle protein metabolism in uremia and other catabolic conditions. Curr Opin Nephrol Hypertens 2005; 14:378-382.
19. Du J, Hu Z, Mitch WE. Molecular mechanisms activating muscle protein degradation in chronic kidney disease and other catabolic conditions. Eur J Clin Invest 2005; 35:157-163.
20. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 2001; 4:183-190.
21. Gayan-Ramirez G, Vanderhoydonc F, Verhoeven G, Decramer M. Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Crit Care Med 1999; 159:283-289.
22. Schakman O, Gilson H, de Coninck V, et al. Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 2005; 146:1789-1797. The authors demonstrate that local gene transfer of IGF-1 prevents steroid induced muscle atrophy.
23. Song YH, Li Y, Du J, et al. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005; 115:451-458. Using a skeletal muscle-specific IGF-1 transgenic model, the authors investigate molecular signaling pathways involved in angiotensin II induced muscle atrophy.
24. DeVol DL, Rotwein P, Sadow JL, et al. Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. Am J Physiol 1990; 259:E89-E95.
25. Vandenburgh HH, Karlisch P, Shansky J, Feldstein R. Insulin and IGF-I induce pronounced hypertrophy of skeletal myofibers in tissue culture. Am J Physiol 1991; 260:C475-C484.
26. Coleman ME, DeMayo F, Yin KC, et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 1995; 270:12109-12116.
27. Musaro A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27:195-200.
28. Barton ER, Morris L, Musaro A, et al. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002; 157:137-148.
29. Rabinovsky ED, Gelir E, Gelir S, et al. Targeted expression of IGF-1 transgene to skeletal muscle accelerates muscle and motor neuron regeneration. Faseb J 2003; 17:53-55.
30. Katic M, Kahn CR. The role of insulin and IGF-1 signaling in longevity. Cell Mol Life Sci 2005; 62:320-343. Reviews the evidence that altered insulin and/or IGF-1 signaling has profound effects on longevity.
31. Dumaz N, Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J 2005; 272:3491-3504.
32. Moelling K, Schad K, Bosse M, et al. Regulation of Raf-Akt Cross-talk. J Biol Chem 2002; 277:31099-31106.
33. Rommel C, Clarke BA, Zimmermann S, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999; 286:1738-1741.
34. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286:1741-1744.
35. Murgia M, Serrano AL, Calabria E, et al. Ras is involved in nerve-activity-dependent regulation of muscle genes. Nat Cell Biol 2000; 2:142-147.
36. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001; 3:1009-1013.
37. Takahashi A, Kureishi Y, Yang J, et al. Myogenic Akt signaling regulates blood vessel recruitment during myofiber growth. Mol Cell Biol 2002; 22:4803-4814.
38. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001; 3:1014-1019.
39. Clement S, Krause U, Desmedt F, et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 2001; 409:92-97.
40. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29-39.
41. Goberdhan DC, Paricio N, Goodman EC, et al. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev 1999; 13:3244-3258.
42. Goberdhan DC, Wilson C. PTEN: tumour suppressor, multifunctional growth regulator and more. Hum Mol Genet 2003; 12:R239-R248.
43. Potter CJ, Pedraza LG, Huang H, Xu T. The tuberous sclerosis complex (TSC) pathway and mechanism of size control. Biochem Soc Trans 2003; 31:584-586.
44. Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002; 110:737-749.
45. Hara K, Yonezawa K, Weng QP, et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and elF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273:14484-14494.
46. Burnett PE, Barrow RK, Cohen NA, et al. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 1998; 95:1432-1437.
47. Nave BT, Ouwens M, Withers DJ, et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999; 344:427-431.
48. Shepherd PR. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol Scand 2005; 183:3-12.
49. Lawrence JC Jr. mTOR-dependent control of skeletal muscle protein synthesis. Int J Sport Nutr Exerc Metab 2001; 11 (Suppl):S177-S185.
50. Pallafacchina G, Calabria E, Serrano AL, et al. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci U S A 2002; 99:9213-9218.
51. Bark TH, McNurlan MA, Lang CH, Garlick PJ. Increased protein synthesis after acute IGF-I or insulin infusion is localized to muscle in mice. Am J Physiol 1998; 275:E118-E123.
52. Musaro A, Rosenthal N. Maturation of the myogenic program is induced by postmitotic expression of insulin-like growth factor I. Mol Cell Biol 1999; 19:3115-3124.
53. Fryburg DA, Jahn LA, Hill SA, et al. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J Clin Invest 1995; 96:1722-1729.
54. Hambrecht R, Schulze PC, Gielen S, et al. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol 2002; 39:1175-1181.
55. Schulze PC, Fang J, Kassik KA, et al. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res 2005; 97:418-426. This paper suggests that transgenic expression of IGF-1 in atrophied skeletal muscle may offer benefit in muscle wasting occurring as a result of ischemic cardiomyopathy.
56. Sjogren K, Liu JL, Blad K, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A 1999; 96:7088-7092.
57. Song YH, Godard M, Li Y, et al. Insulin-like growth factor I-mediated skeletal muscle hypertrophy is characterized by increased mTOR-p70S6K signaling without increased Akt phosphorylation. J Investig Med 2005; 53:135-142. This paper analyses the phosphoprotein profile of skeletal muscle in muscle-specific IGF-1 transgenic mice.
58. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14:395-403. The authors demonstrate that IGF-1 inhibits ubiquitin ligase expression in atrophied muscle via FOXO transcription factors.
59. Du J, Wang X, Miereles C, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 2004; 113:115-123. These authors demonstrate that activated caspase-3 can degrade actin and that this is an initial critical step leading to increased muscle proteolysis.
60. Tintignac LA, Lagirand J, Batonnet S, et al. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem 2005; 280:2847-2856. This paper demonstrates that MyoD is regulated by Atrogin-1 /MAFbx in atrophying muscle.
61. Latres E, Amini AR, Amini AA, et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 2005; 280:2737-2744. The authors characterize the IGF-1/PI3K/Akt signaling pathway in anabolic (hypertrophic) and catabolic (atrophic) conditions.